Merck Announces Presentation Of Phase III Investigational Studies Evaluating DULERA® (Mometasone Furoate And Formoterol Fumarate Dihydrate) Inhalation Aerosol in Chronic Obstructive Pulmonary Disease (COPD)
- 11:40 AM — Oct 27 —
- Source: Pharmaceutical Online
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from two 26-week investigational Phase III clinical studies evaluating the efficacy and safety of two dose strengths of DULERA® (mometasone furoate and formoterol fumarate dihydrate) in adults 40 years and older with moderate to very severe chronic obstructive pulmonary disease (COPD). Read More
Merck Announces Presentation of Phase III Investigational Studies Evaluating DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol in Chronic Obstructive Pulmonary Disease (COPD)
- 4:37 PM — Oct 24 —
- Source: Allegheny Energy Inc
HONOLULU--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from two 26-week investigational Phase III clinical studies evaluating the efficacy and safety of two dose strengths of DULERA ® (mometasone furoate and formoterol fumarate dihydrate) in adults 40 years and older with moderate to very severe chronic obstructive pulmonary disease (COPD). Read More
On Sale
Hot Music News
Adam Levine Romancing New Model
Catwalk Queen Caught Kissing Rocker
Jessica's Shocking Sex Confession
Jessica Simpson's Bedroom Tell-All
Life After Living in the Kardashian Shadow
Singer Fights to Shake the Kardashian Curse
Infertility Struggles Revealed
Joe Nichols Opens Up About Baby Drama